STOCK TITAN
  1. Home
  2. News
  3. KALV

KalVista Pharmaceuticals Inc - KALV STOCK NEWS

Welcome to our dedicated news page for KalVista Pharmaceuticals (Ticker: KALV), a resource for investors and traders seeking the latest updates and insights on KalVista Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect KalVista Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of KalVista Pharmaceuticals's position in the market.

News
KalVista Pharmaceuticals Presents Real-World Data at the 2023 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology
Rhea-AI Summary
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) presented real-world data on anxiety associated with the use of injectable on-demand treatments for hereditary angioedema (HAE) attacks and patient perspectives on why people living with HAE don’t often carry their on-demand treatment outside the home at the 2023 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI) in Anaheim, CA. The company aims to address the significant unmet need for HAE treatment and transform the management of the disease with the potential approval of sebetralstat for the on-demand treatment of HAE. The presentations also covered the global prevalence of normal C1-inhibitor HAE (HAE-nC1-INH) and the varied treatment approaches, highlighting the persisting non-medication health resource utilization among patients receiving long-term prophylaxis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.78%
Tags
none
-
News
KalVista Pharmaceuticals Announces Phase 3 KONFIDENT Trial Milestone Achieved
Rhea-AI Summary
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) provided clinical trial and regulatory updates for its lead program sebetralstat, a potential oral on-demand therapy for hereditary angioedema (HAE). The largest-ever HAE clinical trial, KONFIDENT, has achieved the targeted number of on-treatment attacks required to complete the phase 3 trial. Topline data readout is expected in early 2024, remaining on track for a New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) in the first half of 2024. The Company also expects to file for approval in the European Union and Japan later in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.34%
Tags
clinical trial
-
News
KalVista Pharmaceuticals to Present at Upcoming Investor Conferences
Rhea-AI Summary
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) will participate in investor conferences on November 14 and 16, 2023, presenting at the Stifel 2023 Healthcare Conference and Jefferies London Healthcare Conference. The presentations will be available via live webcast on the company's website, with an audio archive accessible for 30 days after the events.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.65%
Tags
conferences
News
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
KalVista Pharmaceuticals announced the granting of inducement options to eight newly-hired employees. The options allow the purchase of an aggregate of 77,000 shares of KalVista common stock at an exercise price of $8.77 per share. The options vest over a four-year period, subject to continued service with the company.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.06%
Tags
none
-
News
KalVista Pharmaceuticals to Present Data at the 2023 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology
Rhea-AI Summary
KalVista Pharmaceuticals announces acceptance of multiple abstracts at the 2023 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.2%
Tags
conferences
-
News
KalVista Pharmaceuticals Presents Data on HAE Attacks in Patients Receiving Long-Term Prophylaxis at the Asia Pacific Association of Allergy, Asthma and Clinical Immunology 2023 International Conference
Rhea-AI Summary
KalVista Pharmaceuticals presents analysis on hereditary angioedema attacks in patients receiving long-term prophylaxis at APAAACI conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.12%
Tags
none
News
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
KalVista Pharmaceuticals grants 103,000 inducement options to newly-hired employees with an exercise price of $8.98 per share.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.45%
Tags
none
-
News
KalVista Pharmaceuticals to Present at Cantor Global Healthcare Conference
Rhea-AI Summary
KalVista Pharmaceuticals to present at Cantor Global Healthcare Conference on September 27th, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.22%
Tags
conferences
-
News
KalVista Pharmaceuticals Reports First Fiscal Quarter Results and Provides Operational Update
Rhea-AI Summary
KalVista Pharmaceuticals achieves target enrollment for Sebetralstat Phase 3 trial, data readout on track for Q4. Preparations continue for NDA filing in H1 2024 and rapid commercialization upon approval. Key hires and real-world patient data support the efficacy of Sebetralstat. R&D expenses increased to $19.3 million, G&A expenses increased to $9.8 million. Net loss of $25.3 million. Cash position at $123.3 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.6%
Tags
earnings
News
KalVista Pharmaceuticals to Present HAE Attack Journey Data at 2023 HAEi Regional Conference EMEA
Rhea-AI Summary
KalVista Pharmaceuticals accepted multiple abstracts at the 2023 HAEi Regional Conference EMEA meeting. They will also be launching a new patient-focused site called 'Mind the HAE Attack' at HAEi EMEA on September 1.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.46%
Tags
conferences
Stock KALV logo
KalVista Pharmaceuticals Inc

Nasdaq:KALV

KALV Rankings

#2975 Ranked by Market Cap
#326 Ranked by Stock Gains
N/A Ranked by Dividends

KALV Stock Data

501.62M
24.12M
1.14%
92.16%
13.09%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Cambridge

About KALV

kalvista is a clinical stage pharmaceuticals company focused on the discovery, development, and commercialization of small molecule protease inhibitors.